Company intelligence / Profile preview

Porton PharmaTech

Ownership: Private
Employees: ~30
Development stage: Commercial

Overview

Porton PharmaTech is building out state-of-the-art R&D labs and pilot plant facilities in Slovenia. It supports synthesis route development, process scale-up, analytical method validation, and GMP manufacturing. The parent group has extensive experience supporting global pharma/biotech customers from early-stage to commercial production across small molecules and biologics. No clinical results are reported since it does not develop its own drugs

Modalities: Small moleculeBiologicMonoclonal antibodyAntibody-drug conjugatePeptideOligonucleotideADC/AOC/PDC Conjugates
Industry: Contract Manufacturing Organization

Partnerships

Aojin Life Sciences – XDC conjugates CMC/GMP partnershipDragon Sail Pharmaceutical – ADC research/development/supply chain integration partnership

Beyond the preview

Go deeper on Porton PharmaTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Porton PharmaTech.

Explore the full profile